Boston Scientific Corporation 2025-2026 Proxy Voting Records

Description as filed by funds: Proposal to elect ten Directors: David C. Habiger

Boston Scientific Corporation’s own tally for this item (“Elect Director: David C. Habiger”): 1,037,805,652 for, 169,730,106 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 444,992,440 for, 32,670,409 against, 142,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Edward J. Ludwig

Boston Scientific Corporation’s own tally for this item (“Elect Director: Edward J. Ludwig”): 1,156,469,560 for, 50,835,636 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,212,029 for, 450,820 against, 142,672 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Michael F. Mahoney

Boston Scientific Corporation’s own tally for this item (“Elect Director: Michael F. Mahoney”): 1,113,612,016 for, 93,613,027 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,631,074 for, 31,777 against, 142,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Jessica L. Mega

Boston Scientific Corporation’s own tally for this item (“Elect Director: Jessica L. Mega”): 1,196,020,676 for, 11,532,045 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,530,242 for, 132,605 against, 142,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Susan E. Morano

Boston Scientific Corporation’s own tally for this item (“Elect Director: Susan E. Morano”): 1,171,890,417 for, 35,662,932 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,028,420 for, 634,431 against, 142,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Cheryl Pegus

Boston Scientific Corporation’s own tally for this item (“Elect Director: Cheryl Pegus”): 1,195,889,562 for, 11,653,832 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,530,242 for, 132,606 against, 142,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Cathy R. Smith

Boston Scientific Corporation’s own tally for this item (“Elect Director: Cathy R. Smith”): 1,117,908,896 for, 88,044,911 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 459,039,494 for, 18,623,346 against, 142,680 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Christophe P. Weber

Boston Scientific Corporation’s own tally for this item (“Elect Director: Christophe P. Weber”): 1,205,365,637 for, 2,260,256 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,637,842 for, 25,009 against, 142,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: David S. Wichmann

Boston Scientific Corporation’s own tally for this item (“Elect Director: David S. Wichmann”): 1,198,736,185 for, 8,393,038 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,572,623 for, 90,226 against, 142,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: Proposal to elect ten Directors: Ellen M. Zane

Boston Scientific Corporation’s own tally for this item (“Elect Director: Ellen M. Zane”): 1,150,092,668 for, 56,753,553 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 477,214,364 for, 448,480 against, 142,673 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: To amend our Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law.

Boston Scientific Corporation’s own tally for this item (“6. The amendment of the Company's Third Restated Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law”): 1,057,086,923 for, 150,458,633 against — passed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(6) The stockholders approved the amendment of the Company's Third Restated Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 455,686,001 for, 21,951,848 against, 167,670 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

Description as filed by funds: To amend our Certificate of Incorporation to remove supermajority voting provisions.

Boston Scientific Corporation’s own tally for this item (“5. The amendment of the Company's Third Restated Certificate of Incorporation to remove supermajority voting provisions”): 1,189,271,431 for, 17,774,053 against — passed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(5) The stockholders approved the amendment of the Company's Third Restated Certificate of Incorporation to remove supermajority voting provisions.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 203 asset managers below reported 476,415,404 for, 50,103 against, 18 abstained, 1,125 not voted, 24,011 unknown.

Showing the 25 largest of 203 asset managers. See all 203 in the interactive database.

Description as filed by funds: To amend our Certificate of Incorporation and By-Laws to permit stockholders holding 25% of our common stock to call a special meeting of stockholders.

Boston Scientific Corporation’s own tally for this item (“7. The amendment of the Company's Third Restated Certificate of Incorporation and Amended and Restated By-Laws to permit stockholders owning not less than 25% of the Company's common stock to call a special meeting of st”): 1,095,371,430 for, 20,945,183 against — failed, per its Form 8-K filed May 5, 2026 (Item 5.07). This item required more than a simple majority of votes cast — see the filing.

Reported outcome: Not approved, in the filing’s own words: “(7) The stockholders did not approve the amendment of the Company's Third Restated Certificate of Incorporation and Amended and Restated By-Laws to permit stockholders owning not less than 25% of the Company's common stock to call a special meeting of stockholders.”
Not approved: the filing states that this item needed more than a majority of the votes cast.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 203 asset managers below reported 442,213,390 for, 328,263 against, 33,923,684 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 203 asset managers. See all 203 in the interactive database.

Description as filed by funds: To amend our Employee Stock Purchase Plan to increase the number of shares reserved for issuance.

Boston Scientific Corporation’s own tally for this item (“4. The amendment of the Company's Employee Stock Purchase Plan to increase the number of shares reserved for issuance”): 1,205,130,032 for, 2,818,667 against — passed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) The stockholders approved the amendment of the Company's Employee Stock Purchase Plan to increase the number of shares reserved for issuance.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 225 asset managers below reported 480,508,074 for, 151,281 against, 13 abstained, 1,125 not voted, 24,198 unknown.

Showing the 25 largest of 225 asset managers. See all 225 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

Boston Scientific Corporation’s own tally for this item (“2. The compensation of the Company's "Named Executive Officers" as disclosed in the Company's proxy statement for the Annual Meeting”): 1,096,889,576 for, 110,645,813 against — passed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) The stockholders approved, on an advisory basis, the compensation of the Company's "Named Executive Officers" as disclosed in the Company's proxy statement for the Annual Meeting.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Boston Scientific Corporation’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on Pay” (3 managers, 98,123 for, 2,560 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 197 managers: 476,139,242 for, 565,671 against, 142,670 abstained, 1,126 not voted, 24,011 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1,089 managers: 714,886,236 for, 83,702,748 against, 1,151,156 abstained, 377,845 not voted, 187 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2026 fiscal year.

Boston Scientific Corporation’s own tally for this item (“3. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year”): 1,169,955,769 for, 116,874,243 against — passed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 210 asset managers below reported 475,068,164 for, 2,595,580 against, 142,679 abstained, 1,125 not voted, 24,011 unknown.

Showing the 25 largest of 210 asset managers. See all 210 in the interactive database.

Description as filed by funds: Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."

Boston Scientific Corporation’s own tally for this item (“8. The stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."”): 516,140,863 for, 689,739,605 against — failed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “(8) The stockholders did not approve the stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."”
Support: 43% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 207 asset managers below reported 79,987,359 for, 396,960,015 against, 142,680 abstained, 1,125 not voted, 25,007 unknown.

Showing the 25 largest of 207 asset managers. See all 207 in the interactive database.